BMEA vs. ANNX, HRTX, KRRO, MRSN, LXRX, NGNE, CRBP, ESPR, PEPG, and RVNC
Should you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Annexon (ANNX), Heron Therapeutics (HRTX), Korro Bio (KRRO), Mersana Therapeutics (MRSN), Lexicon Pharmaceuticals (LXRX), Neurogene (NGNE), Corbus Pharmaceuticals (CRBP), Esperion Therapeutics (ESPR), PepGen (PEPG), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical preparations" industry.
Annexon (NASDAQ:ANNX) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking.
Annexon received 10 more outperform votes than Biomea Fusion when rated by MarketBeat users. Likewise, 72.41% of users gave Annexon an outperform vote while only 59.26% of users gave Biomea Fusion an outperform vote.
Biomea Fusion's return on equity of -66.54% beat Annexon's return on equity.
Annexon currently has a consensus target price of $14.43, suggesting a potential upside of 196.27%. Biomea Fusion has a consensus target price of $53.25, suggesting a potential upside of 365.07%. Given Annexon's higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Annexon.
96.7% of Biomea Fusion shares are owned by institutional investors. 19.1% of Annexon shares are owned by company insiders. Comparatively, 26.3% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Annexon had 7 more articles in the media than Biomea Fusion. MarketBeat recorded 9 mentions for Annexon and 2 mentions for Biomea Fusion. Annexon's average media sentiment score of 1.18 beat Biomea Fusion's score of 0.53 indicating that Biomea Fusion is being referred to more favorably in the news media.
Biomea Fusion is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.
Annexon has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.33, suggesting that its stock price is 133% less volatile than the S&P 500.
Summary
Annexon beats Biomea Fusion on 10 of the 15 factors compared between the two stocks.
Get Biomea Fusion News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biomea Fusion Competitors List
Related Companies and Tools
